
Tomasz Kucharczyk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3678248/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Septin 9 promoter region methylation in free circulating DNA—potential role in noninvasive diagnosis of lung cancer: preliminary report. Medical Oncology, 2014, 31, 917.	2.5	86
2	Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. Journal of Cancer Research and Clinical Oncology, 2014, 140, 2047-2057.	2.5	28
3	Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncology Reports, 2013, 30, 2385-2398.	2.6	23
4	<i>EGFR</i> gene mutations in patients with adenosquamous lung carcinoma. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 340-345.	1.1	16
5	The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors. Chemotherapy, 2012, 58, 60-69.	1.6	14
6	MicroRNAs aid the assessment of programmed death ligand�1 expression in patients with non‑small cell lung cancer. Oncology Letters, 2019, 17, 5193-5200.	1.8	14
7	Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer — a pilot study. Folia Histochemica Et Cytobiologica, 2012, 50, 80-86.	1.5	13
8	Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients. Frontiers in Oncology, 2020, 10, 563613.	2.8	12
9	The polymorphism of the CHRNA5 gene and the strength of nicotine addiction in lung cancer and COPD patients. European Journal of Cancer Prevention, 2012, 21, 111-117.	1.3	11
10	PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients. Cancer Genetics, 2019, 237, 10-18.	0.4	11
11	Acute hypersensitivity pneumonitis in woodworkers caused by inhalation of birch dust contaminated with <i>Pantoea agglomerans</i> and <i>Microbacterium barkeri</i> . Annals of Agricultural and Environmental Medicine, 2019, 26, 644-655.	1.0	11
12	The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. Pathology and Oncology Research, 2016, 22, 49-56.	1.9	10
13	The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients. Respiration, 2011, 82, 341-350.	2.6	9
14	Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes. Oncotarget, 2017, 8, 64283-64293.	1.8	9
15	Discrepancies between ALK protein disruption and occurrence of ALK gene rearrangement in Polish NSCLC patients. Journal of Thoracic Disease, 2018, 10, 4994-5009.	1.4	7
16	Correlation Between TS, MTHFR, and ERCC1 Gene Polymorphisms and the Efficacy of Platinum in Combination With Pemetrexed First-Line Chemotherapy in Mesothelioma Patients. Clinical Lung Cancer, 2014, 15, 455-465.	2.6	6
17	Screening for <scp>ALK</scp> abnormalities in central nervous system metastases of nonâ€smallâ€cell lung cancer. Brain Pathology, 2018, 28, 77-86.	4.1	6
18	Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy. International Journal of Molecular Sciences, 2021, 22, 9133.	4.1	4

#	Article	IF	CITATIONS
19	Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement. Scientific Reports, 2021, 11, 20939.	3.3	4
20	Impact of copy number variant and single nucleotide polymorphism of the programmed death‑ligand 1 gene, programmed death‑ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non‑small cell lung carcinoma. Oncology Letters, 2021, 21, 449.	1.8	3
21	Ocena rearanżacji genu ROS1 przy pomocy fluorescencyjnej hybrydyzacji in situ w niedrobnokomórkowym raku pÅ,uca. Oncology in Clinical Practice, 2020, 16, 270-275.	0.1	1
22	Poszukiwanie przyczyn opornoÅ›ci na immunoterapiÄ™ pembrolizumabem u chorej na gruczoÅ,owego raka pÅ,uca z ekspresjÄ PD-L1 – mikrobiom jelitowy "pod lupÄ― Oncology in Clinical Practice, 2021, 16, 3	64-368.	0
23	Risk factors and primary prevention of lung cancer. Cessation of cigarette addiction. Oncology in Clinical Practice, 2021, 17, 112-124.	0.1	0